42 related articles for article (PubMed ID: 17634547)
1. Tibolone and Breast Tissue: a Review.
Lello S; Capozzi A; Scambia G; Franceschini G
Reprod Sci; 2023 Dec; 30(12):3403-3409. PubMed ID: 37450250
[TBL] [Abstract][Full Text] [Related]
2. Tissue selective estrogen complex (TSEC): a review.
Pickar JH; Boucher M; Morgenstern D
Menopause; 2018 Sep; 25(9):1033-1045. PubMed ID: 29533367
[TBL] [Abstract][Full Text] [Related]
3. Short-term and long-term effects of tibolone in postmenopausal women.
Formoso G; Perrone E; Maltoni S; Balduzzi S; Wilkinson J; Basevi V; Marata AM; Magrini N; D'Amico R; Bassi C; Maestri E
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD008536. PubMed ID: 27733017
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients.
Drewe J; Bucher KA; Zahner C
Springerplus; 2015; 4():65. PubMed ID: 25713759
[TBL] [Abstract][Full Text] [Related]
5. Climacteric Complaints after Breast Cancer - Is HRT an Option?
Singer CF
Breast Care (Basel); 2008; 3(3):204-209. PubMed ID: 20824041
[TBL] [Abstract][Full Text] [Related]
6. The need for tissue selective menopausal agents.
Eden J
Gynecol Endocrinol; 2005 Jul; 21 Suppl 1():22-7. PubMed ID: 16112952
[TBL] [Abstract][Full Text] [Related]
7. Estrogen and tibolone metabolite levels in blood and breast tissue of postmenopausal women recently diagnosed with early-stage breast cancer and treated with tibolone or placebo for 14 days.
Kloosterboer HJ; Löfgren L; von Schoulz E; von Schoultz B; Verheul HA
Reprod Sci; 2007 Feb; 14(2):151-9. PubMed ID: 17636226
[TBL] [Abstract][Full Text] [Related]
8. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
Martino S; Cauley JA; Barrett-Connor E; Powles TJ; Mershon J; Disch D; Secrest RJ; Cummings SR;
J Natl Cancer Inst; 2004 Dec; 96(23):1751-61. PubMed ID: 15572757
[TBL] [Abstract][Full Text] [Related]
9. Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer.
Dimitrakakis C; Keramopoulos D; Vourli G; Gaki V; Bredakis N; Keramopoulos A
Climacteric; 2005 Dec; 8(4):342-51. PubMed ID: 16390769
[TBL] [Abstract][Full Text] [Related]
10. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
11. Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer.
Dowsett M; Dixon JM; Horgan K; Salter J; Hills M; Harvey E
Clin Cancer Res; 2000 Jun; 6(6):2260-7. PubMed ID: 10873076
[TBL] [Abstract][Full Text] [Related]
12. Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trial.
Kubista E; Planellas Gomez JV; Dowsett M; Foidart JM; Pohlodek K; Serreyn R; Nechushkin M; Manikhas AG; Semiglazov VF; Hageluken CC; Singer CF
Clin Cancer Res; 2007 Jul; 13(14):4185-90. PubMed ID: 17634547
[TBL] [Abstract][Full Text] [Related]
13. Effects of tibolone on the breast of postmenopausal women.
Wang PH; Cheng MH; Chao HT; Chao KC
Taiwan J Obstet Gynecol; 2007 Jun; 46(2):121-6. PubMed ID: 17638619
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]